Literature DB >> 23894157

Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus.

Masahiro Yamamoto1, Mika Yamauchi, Toshitsugu Sugimoto.   

Abstract

CONTEXT: Patients with type 2 diabetes mellitus (T2DM) patients are at increased risk of vertebral fractures (VFs) compared with non-T2DM individuals, because of poor bone quality. Recent studies in nondiabetic subjects have shown that elevated sclerostin levels are associated with VFs independent of bone mineral density (BMD).
OBJECTIVE: We aimed to investigate the association between sclerostin levels and VFs in T2DM. RESEARCH DESIGN AND METHODS: We conducted a cross-sectional observational study in 146 postmenopausal women and 175 men over 50 years old. Sclerostin levels were compared in the patients with and without VFs confirmed by spinal radiographs.
RESULTS: Sclerostin levels were significantly higher in men than in women (P < .01). Stepwise forward multiple regression analyses demonstrated that spine BMD was the strongest and independent positive determinant for sclerostin in both genders. When the participants were divided into 2 subgroups by the T score of spine BMD to eliminate the influence of BMD on sclerostin values, elevated sclerostin levels were associated with an increased risk of VFs in the male patients with BMD T scores ≥-1 (odds ratio = 1.85, 95% confidence interval = 1.12-3.07) and female with T scores <-1 (odds ratio = 3.23, 95% confidence interval = 1.42-7.34) after adjusting for multiple variables including BMD and bone metabolic markers.
CONCLUSIONS: Elevated sclerostin levels were associated with an increased risk of VFs in T2DM patients independently of BMD and bone turnover in both genders, suggesting that sclerostin levels may reflect bone fragility attributed to the deterioration of bone quality under the gender-specific range of BMD T scores.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23894157     DOI: 10.1210/jc.2013-2143

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  23 in total

Review 1.  The role of osteoblasts in energy homeostasis.

Authors:  Naomi Dirckx; Megan C Moorer; Thomas L Clemens; Ryan C Riddle
Journal:  Nat Rev Endocrinol       Date:  2019-08-28       Impact factor: 43.330

2.  Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures.

Authors:  U Heilmeier; D R Carpenter; J M Patsch; R Harnish; G B Joseph; A J Burghardt; T Baum; A V Schwartz; T F Lang; T M Link
Journal:  Osteoporos Int       Date:  2015-01-13       Impact factor: 4.507

Review 3.  The Utility of Biomarkers in Osteoporosis Management.

Authors:  Patrick Garnero
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

4.  Bone cells and bone turnover in diabetes mellitus.

Authors:  Mishaela R Rubin
Journal:  Curr Osteoporos Rep       Date:  2015-06       Impact factor: 5.096

5.  Increased sclerostin and bone turnover after diet-induced weight loss in type 2 diabetes: a post hoc analysis of the MADIAB trial.

Authors:  Rocky Strollo; Andreea Soare; Yeganeh Manon Khazrai; Antonio Di Mauro; Andrea Palermo; Rossella Del Toro; Sara Fallucca; Maria Giovanna Belluomo; Laura Dugo; Mario Pianesi; Paolo Pozzilli; Nicola Napoli
Journal:  Endocrine       Date:  2016-11-25       Impact factor: 3.633

Review 6.  Sclerostin and CKD-MBD.

Authors:  Susan C Schiavi
Journal:  Curr Osteoporos Rep       Date:  2015-06       Impact factor: 5.096

7.  Normal bone density and trabecular bone score, but high serum sclerostin in congenital generalized lipodystrophy.

Authors:  Josivan Gomes Lima; Lucia Helena C Nobrega; Natalia Nobrega Lima; Marcel Catão Ferreira Dos Santos; Maria de Fatima P Baracho; Renaud Winzenrieth; Francisco Bandeira; Carolina de O Mendes-Aguiar; Francisco Paulo Freire Neto; Leonardo Capistrano Ferreira; Clifford J Rosen; Selma Maria B Jeronimo
Journal:  Bone       Date:  2017-04-06       Impact factor: 4.398

Review 8.  Effects of diabetes on osteocytes.

Authors:  Japneet Kaur; Sundeep Khosla; Joshua N Farr
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2022-06-24       Impact factor: 3.626

Review 9.  A review of rodent models of type 2 diabetic skeletal fragility.

Authors:  Roberto J Fajardo; Lamya Karim; Virginia I Calley; Mary L Bouxsein
Journal:  J Bone Miner Res       Date:  2014       Impact factor: 6.741

Review 10.  Impact of Type 2 Diabetes Mellitus and Antidiabetic Medications on Bone Metabolism.

Authors:  Hae Sang Lee; Jin Soon Hwang
Journal:  Curr Diab Rep       Date:  2020-11-27       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.